Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: The IMMEDIATE trial

Katrina Ellis; Y. Zhou; J.R. Beshansky; E. Ainehsazan; Y. Yang; H.P. Selker; G.S. Huggins; L.A. Cupples; I. Peter

doi:10.1038/tpj.2014.41

Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: The IMMEDIATE trial

Katrina Ellis, Y. Zhou, J.R. Beshansky, E. Ainehsazan, Y. Yang, H.P. Selker, G.S. Huggins, L.A. Cupples, I. Peter

The Raine Study

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

© 2015 Macmillan Publishers Limited. The mechanistic effects of intravenous glucose, insulin and potassium (GIK) in cardiac ischemia are not well understood. We conducted a genetic sub-study of the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care (IMMEDIATE) Trial to explore effects of common and rare glucose and insulin-related genetic loci on initial to 6-h and 6- to 12-h change in plasma glucose and potassium. We identified 27 NOTCH2/ADAM30 and 8 C2CD4B variants conferring a 40-57% increase in glucose during the first 6 h of infusion (P

Original language	English
Pages (from-to)	55-62
Journal	Pharmacogenomics Journal
Volume	15
Issue number	1
DOIs	https://doi.org/10.1038/tpj.2014.41
Publication status	Published - 2015

Access to Document

10.1038/tpj.2014.41

Cite this

@article{e9cf8accfbc548e7a9342df8bdf225f4,

title = "Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: The IMMEDIATE trial",

abstract = "{\textcopyright} 2015 Macmillan Publishers Limited. The mechanistic effects of intravenous glucose, insulin and potassium (GIK) in cardiac ischemia are not well understood. We conducted a genetic sub-study of the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care (IMMEDIATE) Trial to explore effects of common and rare glucose and insulin-related genetic loci on initial to 6-h and 6- to 12-h change in plasma glucose and potassium. We identified 27 NOTCH2/ADAM30 and 8 C2CD4B variants conferring a 40-57% increase in glucose during the first 6 h of infusion (P",

author = "Katrina Ellis and Y. Zhou and J.R. Beshansky and E. Ainehsazan and Y. Yang and H.P. Selker and G.S. Huggins and L.A. Cupples and I. Peter",

year = "2015",

doi = "10.1038/tpj.2014.41",

language = "English",

volume = "15",

pages = "55--62",

journal = "Pharmacogenomics Journal",

issn = "1470-269X",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: The IMMEDIATE trial

AU - Ellis, Katrina

AU - Zhou, Y.

AU - Beshansky, J.R.

AU - Ainehsazan, E.

AU - Yang, Y.

AU - Selker, H.P.

AU - Huggins, G.S.

AU - Cupples, L.A.

AU - Peter, I.

PY - 2015

Y1 - 2015

N2 - © 2015 Macmillan Publishers Limited. The mechanistic effects of intravenous glucose, insulin and potassium (GIK) in cardiac ischemia are not well understood. We conducted a genetic sub-study of the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care (IMMEDIATE) Trial to explore effects of common and rare glucose and insulin-related genetic loci on initial to 6-h and 6- to 12-h change in plasma glucose and potassium. We identified 27 NOTCH2/ADAM30 and 8 C2CD4B variants conferring a 40-57% increase in glucose during the first 6 h of infusion (P

AB - © 2015 Macmillan Publishers Limited. The mechanistic effects of intravenous glucose, insulin and potassium (GIK) in cardiac ischemia are not well understood. We conducted a genetic sub-study of the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care (IMMEDIATE) Trial to explore effects of common and rare glucose and insulin-related genetic loci on initial to 6-h and 6- to 12-h change in plasma glucose and potassium. We identified 27 NOTCH2/ADAM30 and 8 C2CD4B variants conferring a 40-57% increase in glucose during the first 6 h of infusion (P

U2 - 10.1038/tpj.2014.41

DO - 10.1038/tpj.2014.41

M3 - Article

C2 - 25135348

VL - 15

SP - 55

EP - 62

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 1

ER -

Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: The IMMEDIATE trial

Abstract

Access to Document

Fingerprint

Cite this